Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

TELA Bio, Inc. - Common stock (NQ:TELA)

1.080 +0.090 (+9.04%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about TELA Bio, Inc. - Common stock

< Previous 1 2 3 4 5 Next >
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio to Take Part in Connecting the Dots
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio to Participate in Piper Sandler’s 35th Annual Healthcare Conference
From TELA Bio, Inc.
Via GlobeNewswire
Recap: TELA Bio Q3 Earnings
Via Benzinga
Recap: TELA Bio Q1 Earnings
Via Benzinga
Why TELA Bio Stock Is Dropping Today
TELA Bio (NASDAQ: TELA) shares are trading lower after the company priced a 4.75 million share offering at $9.50 per share. 
Via Benzinga
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TELA Bio, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
TELA Bio Reports Third Quarter 2023 Financial Results
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio to Announce Third Quarter 2023 Financial Results
From TELA Bio, Inc.
Via GlobeNewswire
Earnings Scheduled For November 9, 2023
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on revenue of $265.00 million. 
Via Benzinga
TELA Bio to Participate in the Gilmartin Group Emerging Growth Company Showcase
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Announces U.S. Commercial Launch of OviTex® PRS Long-Term Resorbable for Plastic and Reconstructive Surgery
New addition expands reconstruction options for surgeons and patients 
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Reports Second Quarter 2023 Financial Results
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio to Announce Second Quarter 2023 Financial Results and Confirms Participation in the Canaccord Genuity 43rd Annual Growth Conference
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio to Participate in the Jefferies Global Healthcare Conference
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Invests in Surgeon Training and Education with Upcoming Cadaver Lab
Company prioritizes education with a variety of in-person and virtual training programs 
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Reports First Quarter 2023 Financial Results
From TELA Bio, Inc.
Via GlobeNewswire
Earnings Scheduled For May 11, 2023
Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its... 
Via Benzinga
TELA Bio Supports Diversity and Inclusion at International Hernia Collaboration Conference
Leader in innovative soft-tissue tissue reconstruction solutions sponsors event advocating for and mentoring women in surgery 
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio to Participate in the JMP Securities Life Sciences Conference
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio to Announce First Quarter 2023 Financial Results
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Announces Pricing of Public Offering of Common Stock
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Announces Proposed Public Offering of Common Stock
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio’s OviTex® Reinforced Tissue Matrix to be Featured in Three Case Reports at SAGES 2023
Presentations highlight utility of this advanced hernia reinforcement material for robotic procedures 
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Announces 510(k) Clearance for OviTex® PRS Long-Term Resorbable for Plastic and Reconstructive Surgery
Company continues design advancements of biologic-based materials for soft tissue repair and reinforcement 
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Reports Fourth Quarter and Full Year 2022 Financial Results
From TELA Bio, Inc.
Via GlobeNewswire
Earnings Scheduled For March 21, 2023
Companies Reporting Before The Bell • LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.20 per share on revenue of $41.75 million. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.